Skip to main content
Erschienen in: Clinical Reviews in Allergy & Immunology 2/2013

01.10.2013

Regaining Tolerance to a Self-antigen by the Modified Vaccination Technique

verfasst von: Arpad Zsigmond Barabas, Chad Douglas Cole, Rene Lafreniere, Donald Mackay Weir

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Autoimmune diseases are initiated and maintained by complex immunopathological processes in environmental and genetic factor predisposed patients. In certain autoimmune diseases, the etiologies and pathogenesis of the conditions are quite well understood; yet in others, controversy surrounds as to why and how auto-injurious processes start. Clinical and laboratory examinations reasonably well define the state of progression/remission of an autoimmune disease and allow treatment according to observed findings. However, none of the presently employed treatment options are specific. In fact, they are all nonspecific in their actions and have undesirable side effects. Over the years, experiments carried out in animals have shed light on the complex immunopathological processes which contribute to disease development and progression. At least one experimental autoimmune kidney disease—which we shall describe—helps to understand how pathogenic autoimmune responses can be terminated specifically, without side effects. Since the new vaccination method—that we call modified vaccination technique—was successfully implemented in an experimental autoimmune disease model called slowly progressive Heymann nephritis for the termination of pathogenic immune responses by a target antigen-specific treatment modality, we shall highlight its use in providing insight to physicians and autoimmunologists for its future implementation in human autoimmune diseases.
Literatur
1.
Zurück zum Zitat Feldmann M, Steinman L (2005) Design of effective immunotherapy for human autoimmunity. Nature 435:612–619PubMedCrossRef Feldmann M, Steinman L (2005) Design of effective immunotherapy for human autoimmunity. Nature 435:612–619PubMedCrossRef
2.
Zurück zum Zitat Arnson Y, Shoenfeld Y, Amital H (2009) Intravenous immunoglobulin therapy for autoimmune diseases. Autoimmunity 42:553–560PubMedCrossRef Arnson Y, Shoenfeld Y, Amital H (2009) Intravenous immunoglobulin therapy for autoimmune diseases. Autoimmunity 42:553–560PubMedCrossRef
3.
Zurück zum Zitat Dorner T, Radbruch A, Burmester GR (2009) B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol 5:433–441PubMedCrossRef Dorner T, Radbruch A, Burmester GR (2009) B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol 5:433–441PubMedCrossRef
4.
Zurück zum Zitat Hogan SL, Muller KE, Jennette JC, Falk RJ (1995) A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis 25:862–875PubMedCrossRef Hogan SL, Muller KE, Jennette JC, Falk RJ (1995) A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis 25:862–875PubMedCrossRef
5.
Zurück zum Zitat Perna A, Schieppati A, Zamora J, Giuliano GA, Braun N, Remuzzi G (2004) Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis 44:385–401PubMed Perna A, Schieppati A, Zamora J, Giuliano GA, Braun N, Remuzzi G (2004) Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis 44:385–401PubMed
6.
Zurück zum Zitat Perosa F, Favoino E, Caragnano MA, Prete M, Dammacco F (2005) CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev 4:526–531PubMedCrossRef Perosa F, Favoino E, Caragnano MA, Prete M, Dammacco F (2005) CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev 4:526–531PubMedCrossRef
7.
Zurück zum Zitat Townsend MJ, Monroe JG, Chan AC (2010) B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev 237:264–283PubMedCrossRef Townsend MJ, Monroe JG, Chan AC (2010) B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev 237:264–283PubMedCrossRef
8.
Zurück zum Zitat Barabas AZ, Cole CD, Barabas AD, Lafreniere R (2004) Production of Heymann nephritis by a chemically modified renal antigen. Int J Exp Pathol 85:277–285PubMedCrossRef Barabas AZ, Cole CD, Barabas AD, Lafreniere R (2004) Production of Heymann nephritis by a chemically modified renal antigen. Int J Exp Pathol 85:277–285PubMedCrossRef
9.
Zurück zum Zitat Weir DM, Pinckard RN (1967) Failure to induce tolerance to rat tissue antigens. Immunology 13:373–380PubMed Weir DM, Pinckard RN (1967) Failure to induce tolerance to rat tissue antigens. Immunology 13:373–380PubMed
10.
Zurück zum Zitat Weir DM, Elson CJ (1969) Antitissue antibodies and immunological tolerance to self. Arthritis Rheum 12:254–260PubMedCrossRef Weir DM, Elson CJ (1969) Antitissue antibodies and immunological tolerance to self. Arthritis Rheum 12:254–260PubMedCrossRef
11.
Zurück zum Zitat Agmon-Levin N, Paz Z, Israeli E, Shoenfeld Y (2009) Vaccines and autoimmunity. Nat Rev Rheumatol 5:648–652PubMedCrossRef Agmon-Levin N, Paz Z, Israeli E, Shoenfeld Y (2009) Vaccines and autoimmunity. Nat Rev Rheumatol 5:648–652PubMedCrossRef
12.
Zurück zum Zitat Biesecker G, Noble B, Andres GA, Koffler D (1984) Immunopathogenesis of Heymann’s nephritis. Clin Immunol Immunopathol 33:333–338PubMedCrossRef Biesecker G, Noble B, Andres GA, Koffler D (1984) Immunopathogenesis of Heymann’s nephritis. Clin Immunol Immunopathol 33:333–338PubMedCrossRef
13.
Zurück zum Zitat Bilsborough J, Viney JL (2002) Getting to the guts of immune regulation. Immunology 106:139–143PubMedCrossRef Bilsborough J, Viney JL (2002) Getting to the guts of immune regulation. Immunology 106:139–143PubMedCrossRef
14.
Zurück zum Zitat Heymann W, Hackel DB, Harwood S, Wilson SG, Hunter JLP (1959) Production of nephritic syndrome in rats by Freund’s adjuvant and rat kidney suspensions. Proc Soc Exp Biol Med 100:660–664PubMedCrossRef Heymann W, Hackel DB, Harwood S, Wilson SG, Hunter JLP (1959) Production of nephritic syndrome in rats by Freund’s adjuvant and rat kidney suspensions. Proc Soc Exp Biol Med 100:660–664PubMedCrossRef
15.
Zurück zum Zitat Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y (2009) Adjuvants and autoimmunity. Lupus 18:1217–1225PubMedCrossRef Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y (2009) Adjuvants and autoimmunity. Lupus 18:1217–1225PubMedCrossRef
16.
Zurück zum Zitat Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y (2009) Infections and autoimmunity—friends or foes? Trends Immunol 30:409–414PubMedCrossRef Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y (2009) Infections and autoimmunity—friends or foes? Trends Immunol 30:409–414PubMedCrossRef
17.
Zurück zum Zitat Molina V, Shoenfeld Y (2005) Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity 38:235–245PubMedCrossRef Molina V, Shoenfeld Y (2005) Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity 38:235–245PubMedCrossRef
18.
Zurück zum Zitat Naito T, Kawamura T, Bannai M et al (2002) Simultaneous activation of natural killer T cells and autoantibody production in mice injected with denatured syngeneic liver tissue. Clin Exp Immunol 129:397–404PubMedCrossRef Naito T, Kawamura T, Bannai M et al (2002) Simultaneous activation of natural killer T cells and autoantibody production in mice injected with denatured syngeneic liver tissue. Clin Exp Immunol 129:397–404PubMedCrossRef
19.
20.
Zurück zum Zitat Edgington TS, Glassock RJ, Dixon FJ (1967) Autologous immune-complex pathogenesis of experimental allergic glomerulonephritis. Science 155:1432–1434PubMedCrossRef Edgington TS, Glassock RJ, Dixon FJ (1967) Autologous immune-complex pathogenesis of experimental allergic glomerulonephritis. Science 155:1432–1434PubMedCrossRef
21.
Zurück zum Zitat Edgington TS, Glassock RJ, Dixon FJ (1968) Autologous immune complex nephritis induced with renal tubular antigen. I. Identification and isolation of the pathogenetic antigen. J Exp Med 127:555–572PubMedCrossRef Edgington TS, Glassock RJ, Dixon FJ (1968) Autologous immune complex nephritis induced with renal tubular antigen. I. Identification and isolation of the pathogenetic antigen. J Exp Med 127:555–572PubMedCrossRef
22.
Zurück zum Zitat Kerjaschki D, Farquhar MG (1982) The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc Natl Acad Sci U S A 79:5557–5581PubMedCrossRef Kerjaschki D, Farquhar MG (1982) The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc Natl Acad Sci U S A 79:5557–5581PubMedCrossRef
23.
Zurück zum Zitat Kerjaschki D, Farquhar MG (1983) Immunocytochemical localization of the Heymann nephritis antigen (GP330) in glomerular epithelial cells of normal Lewis rats. J Exp Med 157:667–686PubMedCrossRef Kerjaschki D, Farquhar MG (1983) Immunocytochemical localization of the Heymann nephritis antigen (GP330) in glomerular epithelial cells of normal Lewis rats. J Exp Med 157:667–686PubMedCrossRef
24.
Zurück zum Zitat Makker SP, Moorthy B (1981) In situ immune complex formation in isolated perfused kidney using homologous antibody. Lab Invest 44:1–5PubMed Makker SP, Moorthy B (1981) In situ immune complex formation in isolated perfused kidney using homologous antibody. Lab Invest 44:1–5PubMed
25.
Zurück zum Zitat Makker SP (1993) Analysis of glomeruli-eluted Gp330 autoantibodies and of Gp330 antigen of Heymann nephritis. J Immunol 151:6500–6508PubMed Makker SP (1993) Analysis of glomeruli-eluted Gp330 autoantibodies and of Gp330 antigen of Heymann nephritis. J Immunol 151:6500–6508PubMed
26.
Zurück zum Zitat Mendrick DL, Noble B, Brentjens JR, Andres GA (1980) Antibody-mediated injury to proximal tubules in Heymann nephritis. Kidney Int 18:328–343PubMedCrossRef Mendrick DL, Noble B, Brentjens JR, Andres GA (1980) Antibody-mediated injury to proximal tubules in Heymann nephritis. Kidney Int 18:328–343PubMedCrossRef
27.
Zurück zum Zitat Neale TJ, Couser WG, Salant DJ, Lowenstein LM, Wilson CB (1982) Specific uptake of Heymann’s nephritic kidney eluate by rat kidney: studies in vivo and in isolated perfused kidneys. Lab Invest 46:450–453PubMed Neale TJ, Couser WG, Salant DJ, Lowenstein LM, Wilson CB (1982) Specific uptake of Heymann’s nephritic kidney eluate by rat kidney: studies in vivo and in isolated perfused kidneys. Lab Invest 46:450–453PubMed
28.
Zurück zum Zitat Neale TJ, Wilson CB (1982) Glomerular antigens in Heymann’s nephritis: reactivity of eluted and circulating antibody. J Immunol 128:323–330PubMed Neale TJ, Wilson CB (1982) Glomerular antigens in Heymann’s nephritis: reactivity of eluted and circulating antibody. J Immunol 128:323–330PubMed
29.
Zurück zum Zitat Tsukada Y, Ono K, Maezawa A, Yano S, Naruse T (1994) A major pathogenic antigen of Heymann nephritis is present exclusively in the renal proximal tubule brush border—studies with a monoclonal antibody against pronase-digested tubular antigen. Clin Exp Immunol 96:303–310PubMedCrossRef Tsukada Y, Ono K, Maezawa A, Yano S, Naruse T (1994) A major pathogenic antigen of Heymann nephritis is present exclusively in the renal proximal tubule brush border—studies with a monoclonal antibody against pronase-digested tubular antigen. Clin Exp Immunol 96:303–310PubMedCrossRef
30.
Zurück zum Zitat Barabas AZ, Weir DM, Cole CD et al (2009) Preventing and treating chronic disorders using the modified vaccination technique. Front Biosci 14:3892–3898CrossRef Barabas AZ, Weir DM, Cole CD et al (2009) Preventing and treating chronic disorders using the modified vaccination technique. Front Biosci 14:3892–3898CrossRef
31.
Zurück zum Zitat Barabas AZ, Cole CD, Barabas AD, Lafreniere R (2004) Down-regulation of pathogenic autoantibody response in a slowly progressive Heymann nephritis kidney disease model. Int J Exp Pathol 85:321–334PubMedCrossRef Barabas AZ, Cole CD, Barabas AD, Lafreniere R (2004) Down-regulation of pathogenic autoantibody response in a slowly progressive Heymann nephritis kidney disease model. Int J Exp Pathol 85:321–334PubMedCrossRef
32.
Zurück zum Zitat Barabas AZ, Cole CD, Barabas AD, Barabas AN, Lafreniere R (2006) Reduced incidence of slowly progressive Heymann nephritis in rats immunized with a modified vaccination technique. Clin Dev Immunol 13:17–24PubMedCrossRef Barabas AZ, Cole CD, Barabas AD, Barabas AN, Lafreniere R (2006) Reduced incidence of slowly progressive Heymann nephritis in rats immunized with a modified vaccination technique. Clin Dev Immunol 13:17–24PubMedCrossRef
33.
Zurück zum Zitat Barabas AZ, Cole CD, Barabas AD, Lafreniere R (2007) Preventative and therapeutic vaccination to combat an experimental autoimmune kidney disease. Biologics Targets Ther 1:59–68 Barabas AZ, Cole CD, Barabas AD, Lafreniere R (2007) Preventative and therapeutic vaccination to combat an experimental autoimmune kidney disease. Biologics Targets Ther 1:59–68
34.
Zurück zum Zitat Barabas AZ, Cole CD, Barabas AD, Lafreniere R (2007) A modified vaccination technique for the prevention and treatment of an experimental autoimmune kidney disease. Ann N Y Acad Sci 1110:619–629PubMedCrossRef Barabas AZ, Cole CD, Barabas AD, Lafreniere R (2007) A modified vaccination technique for the prevention and treatment of an experimental autoimmune kidney disease. Ann N Y Acad Sci 1110:619–629PubMedCrossRef
35.
Zurück zum Zitat Barabas AZ, Cole CD, Barabas AD, Bahlis NJ, Lafreniere R (2007) A vaccination technique to combat presently untreatable chronic ailments. Bioprocess J 6:12–18 Barabas AZ, Cole CD, Barabas AD, Bahlis NJ, Lafreniere R (2007) A vaccination technique to combat presently untreatable chronic ailments. Bioprocess J 6:12–18
36.
Zurück zum Zitat Barabas AZ, Cole CD, Graeff RM, Lafreniere R, Weir DM (2011) The role of autoimmunologists in investigating and treating autoimmune disorders. Autoimmun Rev 10:166–170PubMedCrossRef Barabas AZ, Cole CD, Graeff RM, Lafreniere R, Weir DM (2011) The role of autoimmunologists in investigating and treating autoimmune disorders. Autoimmun Rev 10:166–170PubMedCrossRef
37.
Zurück zum Zitat Barabas AZ, Cole CD, Barabas AD, Lafreniere R (2008) Pathogenic and nonpathogenic autoimmune events—the good and/or the bad? In: Dubois Q (ed) Autoantibodies research progress. Nova Science, Hauppauge, pp 9–18 Barabas AZ, Cole CD, Barabas AD, Lafreniere R (2008) Pathogenic and nonpathogenic autoimmune events—the good and/or the bad? In: Dubois Q (ed) Autoantibodies research progress. Nova Science, Hauppauge, pp 9–18
38.
Zurück zum Zitat Weir DM, Pinckard RN, Elson CJ, Suckling DE (1966) Naturally occurring anti-tissue antibodies in rat sera. Clin Exp Immunol 1:433–442PubMed Weir DM, Pinckard RN, Elson CJ, Suckling DE (1966) Naturally occurring anti-tissue antibodies in rat sera. Clin Exp Immunol 1:433–442PubMed
39.
Zurück zum Zitat Batsford SR, Weghaupt R, Takamiya H, Vogt A (1985) Studies on the mesangial handling of protein antigens: influence of size, charge and biologic activity. Nephron 41:146–151PubMedCrossRef Batsford SR, Weghaupt R, Takamiya H, Vogt A (1985) Studies on the mesangial handling of protein antigens: influence of size, charge and biologic activity. Nephron 41:146–151PubMedCrossRef
40.
Zurück zum Zitat Manson JJ, Mauri C, Ehrenstein MR (2005) Natural serum IgM maintains immunological homeostasis and prevents autoimmunity. Springer Semin Immunopathol 26:425–432PubMedCrossRef Manson JJ, Mauri C, Ehrenstein MR (2005) Natural serum IgM maintains immunological homeostasis and prevents autoimmunity. Springer Semin Immunopathol 26:425–432PubMedCrossRef
41.
Zurück zum Zitat Ogden CA, Kowalewski R, Peng Y, Montenegro V, Elkon KB (2005) IgM is required for efficient complement mediated phagocytosis of apoptotic cells in vivo. Autoimmunity 38:259–264PubMedCrossRef Ogden CA, Kowalewski R, Peng Y, Montenegro V, Elkon KB (2005) IgM is required for efficient complement mediated phagocytosis of apoptotic cells in vivo. Autoimmunity 38:259–264PubMedCrossRef
42.
Zurück zum Zitat Quartier P, Potter PK, Ehrenstein MR, Walport MJ, Botto M (2005) Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrow-derived macrophages in vitro. Eur J Immunol 35:252–260PubMedCrossRef Quartier P, Potter PK, Ehrenstein MR, Walport MJ, Botto M (2005) Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrow-derived macrophages in vitro. Eur J Immunol 35:252–260PubMedCrossRef
43.
Zurück zum Zitat Wermeling F, Karlsson MC, McGaha TL (2009) An anatomical view on macrophages in tolerance. Autoimmun Rev 9:49–52PubMedCrossRef Wermeling F, Karlsson MC, McGaha TL (2009) An anatomical view on macrophages in tolerance. Autoimmun Rev 9:49–52PubMedCrossRef
44.
Zurück zum Zitat Zwart B, Ciurana C, Rensink I, Manoe R, Hack CE, Aarden LA (2004) Complement activation by apoptotic cells occurs predominantly via IgM and is limited to late apoptotic (secondary necrotic) cells. Autoimmunity 37:95–102PubMedCrossRef Zwart B, Ciurana C, Rensink I, Manoe R, Hack CE, Aarden LA (2004) Complement activation by apoptotic cells occurs predominantly via IgM and is limited to late apoptotic (secondary necrotic) cells. Autoimmunity 37:95–102PubMedCrossRef
45.
Zurück zum Zitat Orbach H, Shoenfeld Y (2007) Vaccination infection and autoimmunity: myth and reality VIAMR 2005-10-26-28, Beau-Rivage Palace Hotel, Lausanne, Switzerland. Autoimmun Rev 6:261–266PubMedCrossRef Orbach H, Shoenfeld Y (2007) Vaccination infection and autoimmunity: myth and reality VIAMR 2005-10-26-28, Beau-Rivage Palace Hotel, Lausanne, Switzerland. Autoimmun Rev 6:261–266PubMedCrossRef
46.
47.
Zurück zum Zitat Schoonen WM, Thomas SL, Somers EC et al (2010) Do selected drugs increase the risk of lupus? A matched case–control study. Br J Clin Pharmacol 70:588–596PubMedCrossRef Schoonen WM, Thomas SL, Somers EC et al (2010) Do selected drugs increase the risk of lupus? A matched case–control study. Br J Clin Pharmacol 70:588–596PubMedCrossRef
48.
Zurück zum Zitat Barabas AZ, Cole CD, Barabas AD, Bahlis NJ, Lafreniere R (2008) New vaccination technology for endogenous antigen-derived ailments. IDrugs 11:111–115PubMed Barabas AZ, Cole CD, Barabas AD, Bahlis NJ, Lafreniere R (2008) New vaccination technology for endogenous antigen-derived ailments. IDrugs 11:111–115PubMed
49.
Zurück zum Zitat Barabas AZ, Cole CD, Barabas AD, Lafreniere R (2003) Production of a new model of slowly progressive Heymann nephritis. Int J Exp Pathol 84:245–258PubMedCrossRef Barabas AZ, Cole CD, Barabas AD, Lafreniere R (2003) Production of a new model of slowly progressive Heymann nephritis. Int J Exp Pathol 84:245–258PubMedCrossRef
50.
Zurück zum Zitat Challice J, Barabas AZ, Cornish J, Bruce JW, Lannigan R (1986) Passive Heymann nephritis in pre-and post-natal rats. Br J Exp Pathol 67:915–924PubMed Challice J, Barabas AZ, Cornish J, Bruce JW, Lannigan R (1986) Passive Heymann nephritis in pre-and post-natal rats. Br J Exp Pathol 67:915–924PubMed
51.
52.
Zurück zum Zitat Barabas AZ, Lafreniere R (2005) Antigen-specific down-regulation of immunopathological events in an experimental autoimmune kidney disease. Autoimmun Rev 4:565–570PubMedCrossRef Barabas AZ, Lafreniere R (2005) Antigen-specific down-regulation of immunopathological events in an experimental autoimmune kidney disease. Autoimmun Rev 4:565–570PubMedCrossRef
53.
Zurück zum Zitat Barabas AZ, Cole CD, Barabas AD, Lafreniere R (2006) Downregulation of a pathogenic autoantibody response by IgM autoantibodies directed against the nephritogenic antigen in slowly progressive Heymann nephritis. Pathol Int 56:181–190PubMedCrossRef Barabas AZ, Cole CD, Barabas AD, Lafreniere R (2006) Downregulation of a pathogenic autoantibody response by IgM autoantibodies directed against the nephritogenic antigen in slowly progressive Heymann nephritis. Pathol Int 56:181–190PubMedCrossRef
54.
Zurück zum Zitat Barabas AZ, Cole CD, Weir DM, Lafreniere R (2011) Immunopathological events in an experimental autoimmune kidney disease and how those events can be terminated to regain tolerance to self. In: Petrov M (ed) Autoimmune disorders: symptoms, diagnosis and treatment. Nova Science, Hauppauge, pp 35–66 Barabas AZ, Cole CD, Weir DM, Lafreniere R (2011) Immunopathological events in an experimental autoimmune kidney disease and how those events can be terminated to regain tolerance to self. In: Petrov M (ed) Autoimmune disorders: symptoms, diagnosis and treatment. Nova Science, Hauppauge, pp 35–66
55.
Zurück zum Zitat Barabas AZ, Cole CD, Barabas AD, Lafreniere R (2008) An experimental autoimmune kidney disease caused by pathogenic autoantibodies. In: Petrelli C (ed) New research on autoantibodies. Nova Science, Hauppauge, pp 151–172 Barabas AZ, Cole CD, Barabas AD, Lafreniere R (2008) An experimental autoimmune kidney disease caused by pathogenic autoantibodies. In: Petrelli C (ed) New research on autoantibodies. Nova Science, Hauppauge, pp 151–172
56.
Zurück zum Zitat Barabas AZ, Cole CD, Barabas AD, Barabas AN, Lafreniere R (2006) Effect of rat kidney fraction 3 (rKF3) antigen and specific IgM antibody against rKF3 on the progression of slowly progressive Heymann nephritis. Pathol Int 56:516–529PubMedCrossRef Barabas AZ, Cole CD, Barabas AD, Barabas AN, Lafreniere R (2006) Effect of rat kidney fraction 3 (rKF3) antigen and specific IgM antibody against rKF3 on the progression of slowly progressive Heymann nephritis. Pathol Int 56:516–529PubMedCrossRef
57.
58.
Zurück zum Zitat Greenwald P, Clifford CK, Milner JA (2001) Diet and cancer prevention. Eur J Cancer 37:948–965PubMedCrossRef Greenwald P, Clifford CK, Milner JA (2001) Diet and cancer prevention. Eur J Cancer 37:948–965PubMedCrossRef
59.
60.
Zurück zum Zitat Barabas AZ, Cole CD, Barabas AD, Lafreniere R, Weir DM (2011) Four aspects of autoimmunity and how to regain tolerance to self from an autoimmune disease utilizing the modified vaccination technique. In: Huang FP (ed) Autoimmune disorders—current concepts and advances from bedside to mechanistic insights. InTech, Rijeka, pp 569–590 Barabas AZ, Cole CD, Barabas AD, Lafreniere R, Weir DM (2011) Four aspects of autoimmunity and how to regain tolerance to self from an autoimmune disease utilizing the modified vaccination technique. In: Huang FP (ed) Autoimmune disorders—current concepts and advances from bedside to mechanistic insights. InTech, Rijeka, pp 569–590
61.
Zurück zum Zitat Kerjaschki D (1993) Molecular development of immune deposits and proteinuria in Heymann nephritis. Clin Investig 71:817–821PubMedCrossRef Kerjaschki D (1993) Molecular development of immune deposits and proteinuria in Heymann nephritis. Clin Investig 71:817–821PubMedCrossRef
62.
Zurück zum Zitat Barabas AZ, Cole CD, Barabas AD et al (2004) Presence of immunoglobulin M antibodies around the glomerular capillaries and in the mesangium of normal and passive Heymann nephritis rats. Int J Exp Pathol 85:201–212PubMedCrossRef Barabas AZ, Cole CD, Barabas AD et al (2004) Presence of immunoglobulin M antibodies around the glomerular capillaries and in the mesangium of normal and passive Heymann nephritis rats. Int J Exp Pathol 85:201–212PubMedCrossRef
63.
Zurück zum Zitat Andres G, Brentjens JR, Caldwell PR, Camussi G, Matsuo S (1986) Formation of immune deposits and disease. Lab Invest 55:510–520PubMed Andres G, Brentjens JR, Caldwell PR, Camussi G, Matsuo S (1986) Formation of immune deposits and disease. Lab Invest 55:510–520PubMed
64.
Zurück zum Zitat Barabas AZ, Cole CD, Lafreniere R, Weir DM (2011) Prophylactic and therapeutic application of a new vaccination technique for combating autoimmune disorders. In: Conrad K, Chan EKL, Fritzler MJ, Humbel RL, Meroni PL, Shoenfeld Y (eds) From prediction to prevention of autoimmune diseases—report on the 10th Dresden symposium on autoantibodies held in Dresden on September 22–25, 2011. PABST Science, Berlin, pp 519–539 Barabas AZ, Cole CD, Lafreniere R, Weir DM (2011) Prophylactic and therapeutic application of a new vaccination technique for combating autoimmune disorders. In: Conrad K, Chan EKL, Fritzler MJ, Humbel RL, Meroni PL, Shoenfeld Y (eds) From prediction to prevention of autoimmune diseases—report on the 10th Dresden symposium on autoantibodies held in Dresden on September 22–25, 2011. PABST Science, Berlin, pp 519–539
65.
Zurück zum Zitat Kerjaschki D, Neale TJ (1996) Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis). J Am Soc Nephrol 7:2518–2526PubMed Kerjaschki D, Neale TJ (1996) Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis). J Am Soc Nephrol 7:2518–2526PubMed
66.
Zurück zum Zitat Ronco P, Debiec H (2006) Molecular dissection of target antigens and nephritogenic antibodies in membranous nephropathy: towards epitope-driven therapies. J Am Soc Nephrol 17:1772–1774PubMedCrossRef Ronco P, Debiec H (2006) Molecular dissection of target antigens and nephritogenic antibodies in membranous nephropathy: towards epitope-driven therapies. J Am Soc Nephrol 17:1772–1774PubMedCrossRef
67.
Zurück zum Zitat Ronco P, Debiec H (2006) New insights into the pathogenesis of membranous glomerulonephritis. Curr Opin Nephrol Hypertens 15:258–263PubMedCrossRef Ronco P, Debiec H (2006) New insights into the pathogenesis of membranous glomerulonephritis. Curr Opin Nephrol Hypertens 15:258–263PubMedCrossRef
68.
Zurück zum Zitat Boes M, Schmidt T, Linkemann K, Beaudette BC, Marshak-Rothstein A, Chen J (2000) Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci U S A 97:1184–1189PubMedCrossRef Boes M, Schmidt T, Linkemann K, Beaudette BC, Marshak-Rothstein A, Chen J (2000) Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci U S A 97:1184–1189PubMedCrossRef
69.
Zurück zum Zitat Gullstrand B, Martensson U, Sturfelt G, Bengtsson AA, Truedsson L (2009) Complement classical pathway components are all important in clearance of apoptotic and secondary necrotic cells. Clin Exp Immunol 156:303–311PubMedCrossRef Gullstrand B, Martensson U, Sturfelt G, Bengtsson AA, Truedsson L (2009) Complement classical pathway components are all important in clearance of apoptotic and secondary necrotic cells. Clin Exp Immunol 156:303–311PubMedCrossRef
70.
Zurück zum Zitat Mevorach D, Mascarenhas JO, Gershov D, Elkon KB (1998) Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med 188:2313–2320PubMedCrossRef Mevorach D, Mascarenhas JO, Gershov D, Elkon KB (1998) Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med 188:2313–2320PubMedCrossRef
71.
Zurück zum Zitat Pereira WO, Amarante-Mendes GP (2011) Apoptosis: a programme of cell death or cell disposal? Scand J Immunol 73:401–407PubMedCrossRef Pereira WO, Amarante-Mendes GP (2011) Apoptosis: a programme of cell death or cell disposal? Scand J Immunol 73:401–407PubMedCrossRef
72.
Zurück zum Zitat Pinckard RN, Weir DM (1966) Antibodies against the mitochondrial fraction of liver after toxic liver damage in rats. Clin Exp Immunol 1:33–43PubMed Pinckard RN, Weir DM (1966) Antibodies against the mitochondrial fraction of liver after toxic liver damage in rats. Clin Exp Immunol 1:33–43PubMed
73.
Zurück zum Zitat Noble B, Van Liew JB, Brentjens JR, Andres GA (1982) Effect of reimmunization with Fx1A late in the course of Heymann nephritis. Lab Invest 47:427–436PubMed Noble B, Van Liew JB, Brentjens JR, Andres GA (1982) Effect of reimmunization with Fx1A late in the course of Heymann nephritis. Lab Invest 47:427–436PubMed
74.
75.
Zurück zum Zitat Rao T, Richardson B (1999) Environmentally induced autoimmune diseases: potential mechanisms. Environ Health Perspect 107(Suppl 5):737–742PubMedCrossRef Rao T, Richardson B (1999) Environmentally induced autoimmune diseases: potential mechanisms. Environ Health Perspect 107(Suppl 5):737–742PubMedCrossRef
76.
77.
Zurück zum Zitat Ebringer A, Thorpe C, Pirt J, Wilson C, Cunningham P, Ettelaie C (1997) Bovine spongiform encephalopathy: is it an autoimmune disease due to bacteria showing molecular mimicry with brain antigens? Environ Health Perspect 105:1172–1174PubMedCrossRef Ebringer A, Thorpe C, Pirt J, Wilson C, Cunningham P, Ettelaie C (1997) Bovine spongiform encephalopathy: is it an autoimmune disease due to bacteria showing molecular mimicry with brain antigens? Environ Health Perspect 105:1172–1174PubMedCrossRef
78.
Zurück zum Zitat Ebringer A (2003) Molecular mimicry as the basis of a new theory of autoimmunity. In: Zouali M (ed) Frontiers in autoimmunity: fundamental aspects and clinical perspectives. Ios, Amsterdam, pp 79–99 Ebringer A (2003) Molecular mimicry as the basis of a new theory of autoimmunity. In: Zouali M (ed) Frontiers in autoimmunity: fundamental aspects and clinical perspectives. Ios, Amsterdam, pp 79–99
79.
Zurück zum Zitat Ebringer A, Hughes L, Rashid T, Wilson C (2005) Acinetobacter immune responses in multiple sclerosis: etiopathogenetic role and its possible use as a diagnostic marker. Arch Neurol 62:33–36PubMedCrossRef Ebringer A, Hughes L, Rashid T, Wilson C (2005) Acinetobacter immune responses in multiple sclerosis: etiopathogenetic role and its possible use as a diagnostic marker. Arch Neurol 62:33–36PubMedCrossRef
80.
Zurück zum Zitat Ebringer A, Rashid T (2009) Rheumatoid arthritis is caused by proteus: the molecular mimicry theory and Karl Popper. Front Biosci (Elite Ed) 1:577–586 Ebringer A, Rashid T (2009) Rheumatoid arthritis is caused by proteus: the molecular mimicry theory and Karl Popper. Front Biosci (Elite Ed) 1:577–586
81.
Zurück zum Zitat Barabas AZ, Cole CD, Lafreniere R, Weir DM (2012) Immunopathological events initiated and maintained by pathogenic IgG autoantibodies in an experimental autoimmune kidney disease. Autoimmunity 45:495–509PubMedCrossRef Barabas AZ, Cole CD, Lafreniere R, Weir DM (2012) Immunopathological events initiated and maintained by pathogenic IgG autoantibodies in an experimental autoimmune kidney disease. Autoimmunity 45:495–509PubMedCrossRef
82.
Zurück zum Zitat Barabas AZ, Cole CD, Barabas AD, Graeff RM, Lafreniere R, Weir DM (2010) Modified vaccination technique for prophylactic and therapeutic applications to combat endogenous antigen-induced disorders. Scand J Immunol 71:125–133PubMedCrossRef Barabas AZ, Cole CD, Barabas AD, Graeff RM, Lafreniere R, Weir DM (2010) Modified vaccination technique for prophylactic and therapeutic applications to combat endogenous antigen-induced disorders. Scand J Immunol 71:125–133PubMedCrossRef
83.
Zurück zum Zitat Barabas AZ, Cole CD, Kovacs ZB, Lafreniere R (2007) Elevated antibody response by antigen presentation in immune complexes. Med Sci Monit 13:BR119–BR124PubMed Barabas AZ, Cole CD, Kovacs ZB, Lafreniere R (2007) Elevated antibody response by antigen presentation in immune complexes. Med Sci Monit 13:BR119–BR124PubMed
84.
Zurück zum Zitat Barabas AZ, Cole CD, Sensen M, Lafreniere R (2012) Production of heterologous IgG antibody against Heymann nephritis antigen by injections of immune complexes. Int J Exp Pathol 93:11–17PubMedCrossRef Barabas AZ, Cole CD, Sensen M, Lafreniere R (2012) Production of heterologous IgG antibody against Heymann nephritis antigen by injections of immune complexes. Int J Exp Pathol 93:11–17PubMedCrossRef
85.
Zurück zum Zitat Avrameas S (1991) Natural autoantibodies: from ‘horror autotoxicus’ to ‘gnothi seauton’. Immunol Today 12:154–159PubMed Avrameas S (1991) Natural autoantibodies: from ‘horror autotoxicus’ to ‘gnothi seauton’. Immunol Today 12:154–159PubMed
86.
Zurück zum Zitat Radbruch A, Muehlinghaus G, Luger EO et al (2006) Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 6:741–750PubMedCrossRef Radbruch A, Muehlinghaus G, Luger EO et al (2006) Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 6:741–750PubMedCrossRef
Metadaten
Titel
Regaining Tolerance to a Self-antigen by the Modified Vaccination Technique
verfasst von
Arpad Zsigmond Barabas
Chad Douglas Cole
Rene Lafreniere
Donald Mackay Weir
Publikationsdatum
01.10.2013
Verlag
Springer US
Erschienen in
Clinical Reviews in Allergy & Immunology / Ausgabe 2/2013
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-012-8350-y

Weitere Artikel der Ausgabe 2/2013

Clinical Reviews in Allergy & Immunology 2/2013 Zur Ausgabe

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.